| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:bdfc40da1d94ca6e","evidence_event_ids":["evt_0b8215cbc584"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","company":"Taysha Gene Therapies, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","article_chars":2060,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_77b34095537a767c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","content_type":"text/plain","enriched_at":"2026-04-11T06:07:32.469733+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt","source_event_id":"evt_0b8215cbc584","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"8094ad1bf6c4d7cb","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-10","2026-06-11","2025-06-11","2024-01-02","2025-01-02","2026-01-12"],"entities":[{"asset_class":"equity","name":"Taysha Gene Therapies, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Nagendran Sukumar","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Jefferies LLC","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["The text provided does not include the full Form 144 table structure/column headers, so the meaning of each numeric field (e.g., whether amounts are shares vs. aggregate price) is not fully verifiable from the excerpt.","The signal does not include any prior known state to compare what changed (e.g., whether this is a new filing vs. an update).","No explicit total shares to be sold or total aggregate sale price is clearly labeled in the provided text beyond the line-item numbers shown."],"key_facts":["SEC accession number: 0001974158-26-000040.","Conformed submission type: Form 144.","Filed as of date and date as of change: 2026-04-10.","Subject company/issuer: Taysha Gene Therapies, Inc. (CIK 0001806310; SEC file number 001-39536).","Reporting owner: Nagendran Sukumar (CIK 0001665124).","Security type indicated: Nasdaq Common.","Transaction context includes: \u201cAll Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 6/11/2025.\u201d","The filing includes multiple grant references dated 01/02/2024 and 01/02/2025 (RSU Grant) and 01/02/2024 (Stock Option Grant), with quantities shown in the text (e.g., 200000; 131550; 49429; 19021).","The filing includes a sale date range/target date shown as 01/12/2026 for one line item."],"numeric_claims":[{"label":"Form 144 filed date","value":"2026-04-10"},{"label":"10b5-1 plan adoption date","value":"2025-06-11"},{"label":"Quantity shown (one line)","value":"200000"},{"label":"Quantity shown (one line)","value":"131550"},{"label":"Quantity shown (one line)","value":"49429"},{"label":"Quantity shown (one line)","value":"19021"},{"label":"Price/amount shown (one line)","value":"926000.00"},{"label":"Price/amount shown (one line)","value":"287000000"},{"label":"Price/amount shown (one line)","value":"942740.00"}],"primary_claim":"On 2026-04-10, Taysha Gene Therapies, Inc. filed SEC Form 144 (accession 0001974158-26-000040) for common stock resale by reporting owner Nagendran Sukumar under a 10b5-1 selling plan dated 6/11/2025.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Taysha Gene Therapies, Inc. filed a Form 144 on 2026-04-10 disclosing planned resale activity by reporting owner Nagendran Sukumar for common stock. The filing states sales will be made under a previously adopted 10b5-1 selling plan dated 2026-06-11.","topics":["SEC Form 144","insider resale","10b5-1 selling plan","common stock","Taysha Gene Therapies"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Taysha Gene Therapies, Inc. \u00b7 Filed 20260410","ticker":"TSHA","tickers":["TSHA"],"title":"TSHA filed 144","url":"https://www.sec.gov/Archives/edgar/data/1806310/0001974158-26-000040.txt"}}... |